Component
Recurrent herpes simplex episodes
Independent cellular process record; interpretation is limited by each linked claim and its study context.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The 1980 crossover trial found no overall reduction in herpes-labialis recurrence or healing time with 1 g daily lysine, despite more recurrence-free participants.
Experimental context and source evidence
- experimental_model
- Double-blind crossover clinical trial in 65 patients
- limitations
- Twelve-week treatment periods; outcome definition and regimen differ from the later positive trial.
- organism
- Homo sapiens
- plain_language
- The average recurrence and healing results were negative, although one secondary pattern favored treatment.
- primary_references
- [milman1980] Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. (1980). https://medicaljournalssweden.se/actadv/article/view/10630 DOI: 10.2340/00015555608587
- tissue_or_cell_type
- Lip herpes lesions
L-Lysine: mechanism-first literature curation (2026-09-17) · lines 679–687
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind crossover clinical trial in 65 patients · source_derived_draft · unverified_draft
### hsv-recurrence-null-trial The 1980 crossover trial found no overall reduction in herpes-labialis recurrence or healing time with 1 g daily lysine, despite more recurrence-free participants. Plain language: The average recurrence and healing results were negative, although one secondary pattern favored treatment. Condition category: normal organism: Homo sapiens tissue_or_cell_type: Lip herpes lesions experimental_model: Double-blind crossover clinical trial in 65 patients limitations: Twelve-week treatment periods; outcome definition and regimen differ from the later positive trial. [milman1980] Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. (1980). https://medicaljournalssweden.se/actadv/article/view/10630 DOI: 10.2340/00015555608587
Complete structured claim and evidenceThe 1987 trial reported fewer recurrent HSV episodes with lysine than placebo among completers receiving 1 g three times daily for six months.
Experimental context and source evidence
- experimental_model
- Double-blind placebo-controlled multicenter clinical trial
- limitations
- 52 completers; reported symptom/healing findings do not prove direct viral inhibition; intake is a studied regimen, not a recommendation.
- organism
- Homo sapiens
- plain_language
- One small trial favored lysine for recurrence prevention.
- primary_references
- [griffith1987] Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. (1987). https://pubmed.ncbi.nlm.nih.gov/3115841/ DOI: 10.1159/000248823
- tissue_or_cell_type
- Clinical mucocutaneous HSV outcomes
L-Lysine: mechanism-first literature curation (2026-09-17) · lines 669–677
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind placebo-controlled multicenter clinical trial · source_derived_draft · unverified_draft
### hsv-recurrence-positive-trial The 1987 trial reported fewer recurrent HSV episodes with lysine than placebo among completers receiving 1 g three times daily for six months. Plain language: One small trial favored lysine for recurrence prevention. Condition category: normal organism: Homo sapiens tissue_or_cell_type: Clinical mucocutaneous HSV outcomes experimental_model: Double-blind placebo-controlled multicenter clinical trial limitations: 52 completers; reported symptom/healing findings do not prove direct viral inhibition; intake is a studied regimen, not a recommendation. [griffith1987] Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. (1987). https://pubmed.ncbi.nlm.nih.gov/3115841/ DOI: 10.1159/000248823
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.